Acrivon Therapeutics (ACRV) Institutional Ownership $6.50 +0.12 (+1.88%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$19.75MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$674.56K Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024 Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024 Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024 State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024 Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/16/2024 Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024 Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024 Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024 XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024 Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024 Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024 Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% 5/15/2024 Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% 5/14/2024 American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024 Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023 Barclays PLC14,263$184K0.0%-16.0%0.065% 8/10/2023 AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023 RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023 Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023 NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023 Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward) ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 22 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($55.42M), Perceptive Advisors LLC ($31.09M), Sands Capital Ventures LLC ($12.31M), Marshall Wace LLP ($5.50M), NEA Management Company LLC ($4.44M), Vanguard Group Inc. ($3.63M), and HealthCor Management L.P. ($3.27M).Learn more on ACRV's institutional investors. What percentage of Acrivon Therapeutics stock is owned by institutional investors? 71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics stock? Of the 18 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($4.81M), Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($2.12M), NEA Management Company LLC ($481.68K), Marshall Wace LLP ($351.40K), HealthCor Management L.P. ($284.20K), and Baker BROS. Advisors LP ($52.89K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 10,665,254 shares in the last 24 months. This purchase volume represents approximately $103.81M in transactions. Which Acrivon Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Acrivon Therapeutics stock in the last 24 months: Federated Hermes Inc. ($287.71K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($27.71K), Exchange Traded Concepts LLC ($22.52K), Geode Capital Management LLC ($6.29K), and Barclays PLC ($2.72K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 395,042 shares in the last 24 months. This volume of shares sold represents approximately $4.12M in transactions. Related Companies Erasca Institutional Ownership Autolus Therapeutics Institutional Ownership Evolus Institutional Ownership Pliant Therapeutics Institutional Ownership Cronos Group Institutional Ownership Cullinan Therapeutics Institutional Ownership Prothena Institutional Ownership Replimune Group Institutional Ownership CARGO Therapeutics Institutional Ownership Anavex Life Sciences Institutional Ownership This page (NASDAQ:ACRV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.